Table 3.
Ongoing clinical trials with apatinib
| Conditions | Identifier | Phase | Design | Agents | State |
|---|---|---|---|---|---|
| Gastric cancer | NCT03333967 | – | Real-world study | Apatinib | Recruiting |
| NCT03271073 | II | Open label: single group assignment | Apatinib and S-1 | Recruiting | |
| NCT03229096 | II | Open label: single group assignment | Apatinib and XELOX | Recruiting | |
| NCT03144843 | II | Double blind, multicenter Randomized parallel assignment |
Apatinib and paclitaxol | Recruiting | |
| NCT03007446 | II | Open label: single group assignment | Apatinib, oxaliplatin and S-1 | Recruiting | |
| Breast cancer | NCT03086785 | II | Open label: multicenter, observational study | Apatinib and capecitabine | Recruiting |
| NCT03348098 | II | Open label: single group assignment | Apatinib and paclitaxel | Recruiting | |
| NCT02768415 | II | Open label: single group assignment | Apatinib and oral vinorelbine | Recruiting | |
| Lung cancer | NCT02995187 | II | Open label: single group assignment | Apatinib | Recruiting |
| NCT03164694 | II | Open label: randomized parallel assignment | Apatinib, pemetrexed, and carboplatin | Recruiting | |
| NCT03256721 | II | Double-blind randomized parallel assignment | Apatinib, docetaxel, and pemetrexed | Recruiting | |
| Esophageal squamous cell carcinoma | NCT03251417 | II | Open label: single group assignment | Apatinib and irinotecan | Recruiting |
| Nasopharyngeal carcinoma | NCT03180476 | II | Open label: single group assignment | Apatinib | Recruiting |
| Osteosarcoma | NCT02711007 | II/III | Open label: single group assignment | Apatinib | Recruiting |
| Intrahepatic cholangiocarcinoma | NCT03251443 | III | Open label: single group assignment | Apatinib | Recruiting |